Patients were treated with SSZ (n = 26, 68.4%), MTX (n = 11, 28.9%) and anti-TNFα agents (n = 13, 34.2%); because of recurrent and/or severe uveitis (n = 22, 57.9%), inflammatory rheumatism (n = 11, 28.9%) or for both (n = 5, 13.2%). Here, TNF is linked to uveitis.